L-arginine evokes both endothelium-dependent and -independent relaxations in L-arginine-depleted aortas of the rat.
This study was designed to investigate the effects of L-arginine (the substrate for the formation of endothelium-derived nitric oxide) in vascular tissues. Rat aortic rings, with or without endothelium, were suspended in organ chambers for the measurement of isometric tension; they were contracted with phenylephrine (10(-6) M). After a short incubation period (0.5 hour) in physiological salt solution, L-arginine induced minor changes in both types of rings. In contrast, when the incubation time was increased (2, 4, 6, and 8 hours), L-arginine evoked concentration- and time-dependent relaxations in aortic rings both with and without endothelium. The relaxations were larger in rings with endothelium. The presence of L-arginine (10(-3) M) in the incubation medium inhibited subsequent relaxations evoked by the amino acid. The concentration-relaxation curves associated with acetylcholine in rings with endothelium and the curves associated with Sin-1, a spontaneous donor of nitric oxide, in rings with or without endothelium were slightly but significantly shifted to the right after a 6-hour incubation. Nitro-L-arginine (3 x 10(-5) M) and methylene blue (3 x 10(-7) M) attenuated the relaxations evoked by L-arginine in rings both with and without endothelium. Other basic amino acids (D-arginine, L-homoarginine, L-citrulline, L-lysine, and L-ornithine; all tested at 10(-3) M) either had no effect or induced small relaxations and did not affect the response to L-arginine. These observations suggest that L-arginine specifically and stereoselectively relaxes aortic rings with and without endothelium, probably by restoring the endogenous pool of the amino acid, which is likely depleted by prolonged incubation.(ABSTRACT TRUNCATED AT 250 WORDS)
Schini
V B
VB
Center for Experimental Therapeutics, Baylor College of Medicine, Houston, TX 77030.
Vanhoutte
P M
PM
D000109:Acetylcholine / Q000494:pharmacology; D000596:Amino Acids / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects* / Q000378:metabolism; D001120:Arginine / Q000172:deficiency / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000378:metabolism / Q000502:physiology*; D008297:Male; D008981:Molsidomine / Q000031:analogs & derivatives / Q000494:pharmacology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000378:metabolism; D010656:Phenylephrine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014664:Vasodilation; D014665:Vasodilator Agents / Q000494:pharmacology
D000596:Amino Acids; D014665:Vasodilator Agents; D010656:Phenylephrine; D009569:Nitric Oxide; C002385:linsidomine; D001120:Arginine; D008981:Molsidomine; D000109:Acetylcholine